Aarhus, Denmark, 13 May 2025 – NMD Pharma A/S, a clinical-stage biotech company dedicated to developing novel and improved treatments for patients living with neuromuscular diseases, today announces ...
The MarketWatch News Department was not involved in the creation of this content. NMD Pharma presents preclinical data highlighting increased innervation of skeletal muscle with ClC-1 ion channel ...
NMD Pharma to present compelling preclinical data highlighting the potential of ClC-1 ion channel inhibition to improve disease symptoms and progression in MuSK myasthenia gravis at the MGFA ...
Aarhus, Denmark, 25 March 2025 – NMD Pharma A/S, a clinical-stage biotech company dedicated to developing novel and improved treatments for patients living with neuromuscular diseases, today announces ...
Company presented clinical and preclinical data at the MDA Conference last week in Dallas, Texas Oral presentation included data from MuSK-MG rat model depicting increases in muscle function and ...
The Company continues to progress its Phase 2b clinical study in generalized myasthenia gravis (gMG) patients who are AChR and MuSK antibody positive, investigating the potential of NMD670 and its ...
NMD Pharma to present compelling preclinical data highlighting the potential of ClC-1 ion channel inhibition to improve disease symptoms and progression in MuSK myasthenia gravis at the MGFA ...
Chloride channels, particularly those of the CLC family, are vital for cellular homeostasis by facilitating the exchange of chloride ions and protons across membranes. These transport proteins govern ...
Unele rezultate au fost ascunse, deoarece pot fi inaccesibile pentru dvs.
Afișați rezultatele inaccesibile